Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
A phase 3 trial testing Darovasertib in uveal melanoma, now recruiting.
Overview
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma is a phase 3 interventional study registered as NCT07804186, led by IDEAYA Biosciences, and recruiting when checked on 2026-09-11. Official title: A Randomised, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma. Planned enrolment is 450 participants (estimated). The study started in 2026-09 and primary completion is expected in 2034-03. No results have been posted on ClinicalTrials.gov.
Setting
A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Phase
Phase 3
Sponsor
IDEAYA Biosciences
Registry
Enrolled
450
Similar pages
not linked directly; found by shared links- TrialNeoadjuvant Darovasertib in Primary Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma and the tag ctgov-ingest.